NEWSROOM

Stay current with MiRXES

Newsroom > Media Releases

MiRXES Welcomes Professor Tony Mok to Scientific Advisory Board

SINGAPORE, 12 April 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company focused on improving and saving lives with miRNA-powered cancer early detection tests, announced today the appointment of Professor Tony Mok, a world-renowned medical oncologist, to its Scientific Advisory Board (SAB). Professor Mok co-founded the Lung Cancer Research Group, Chinese Thoracic Oncology Research Group and Asia Thoracic Oncology Research Group and has led multiple multi-national studies that help establish the global standard on personalized medicine for lung cancer. His expertise in biomarker and molecular targeted therapy in lung cancer will further strengthen MiRXES’s scientific pursuit to discover novel cancer biomarkers and to accelerate the clinical deployment of blood-based lung cancer and multi-cancer screening tests.

Professor Mok is the Li Shu Fan Medical Foundation endowed Professor and Chairman of Department of Clinical Oncology at the Chinese University of Hong Kong. He was the Principal Investigator and first author on the landmark IRESSA® Pan-Asia Study (IPASS), which was the first study that confirmed the application of precision medicine for advanced lung cancer. He has also led and co-led multiple international phase III studies including the FASTACT 2, PROFILE 1014, IMPRESS, ARCHER 1050, ALEX, AURA 3 and KEYNOTE 042. These projects address various aspects on management of advanced lung cancer, and basically have defined the current practice. Professor Mok is active in international education activity and has made significant contribution to AACR, ASCO, CSCO and ESMO. He believes that is it essential for a medical doctor to embrace what biotechnology has to offer and deliver the best patient outcome in a patient’s entire care continuum.

 

“I am thrilled to join the MiRXES SAB on this exciting journey to enable a future where cancers are detected early and cured. I look forward to working with MiRXES’s talented scientific and management teams in groundbreaking miRNA-powered multi-omics research and clinical translation, in the field of cancer early detection and precision medicine,” said Professor Mok, who is currently also a member of the Board of Directors for ASCO, ACT-Sanomics Group, AstraZeneca, Aurora Tele-Oncology and HutchMed (China).

Professor Mok has contributed to over 270 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet, Nature Medicine and Journal of Clinical Oncology, and published multiple editorials and textbooks. He served as an Associate Editor for thoracic oncology for the Journal of Clinical Oncology and other international journals. His work was recognized by numerous awards with the latest being Giant of Cancer Care 2020 and SingTao Hong Kong Leader of the Year 2020 Award. 

“It is our honor and privilege to welcome Professor Mok to our SAB. We share a common vision to eradicate cancer death through early detection and precision medicine. The MiRXES team looks forward to leveraging the deep scientific insights and clinical expertise of Professor Mok and other members of our accomplished, international SAB, to explore the uncharted frontier in genomic research and cancer diagnostics,” said Dr. Lihan ZHOU, Co-founder and CEO of MiRXES.

More information on the MiRXES SAB here.

About MiRXES

Founded in 2014 as a spin-off from Singapore’s Agency for Science, Technology, and Research (A*STAR) with strong support from the National University of Singapore (NUS), MiRXES is a leading developer of RNA-powered tests for disease early detection, with strong pipelines in multiple cancer types, as well as in cardiovascular, metabolic and infectious diseases. MiRXES is headquartered in Singapore, with operations in China, Japan and the United States, as well as commercial activities in over 45 countries globally. In 2019, MiRXES launched GASTROClear, the world’s first microRNA blood test for early detection of gastric cancer. The MiRXES’s multi-cancer early detection pipeline includes screening tests for lung, colorectal, liver, and breast cancer. In response to the COVID-19 pandemic in 2020, MiRXES worked closely with A*STAR, Diagnostics Development Hub (DxD) and Tan Tock Seng Hospital (TTSH) to mass produce Fortitude Kit, Singapore’s first authorized COVID-19 RT-PCR test. Since February 2020, more than 8 million Fortitude Kits have been deployed globally.

For more information, visit www.mirxes.com

Follow us on LinkedIn @ https://www.linkedin.com/company/mirxes/

Copyright © 2021 MiRXES Pte Ltd. All rights reserved. | Privacy Policy
Scroll to Top